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Abstract
Background: The aims of this study were to detect HPV E6/E7 mRNA expression in women with high-risk
genotypes (HPV-16, -18, -31, -33 and -45) analysing its relationship with tissue pathology and 2) 2-year follow-up of
E6/E7 mRNA tested group.
Methods: Our samples were genotyped and classified by pathologists according to Bethesda system. After RNA
extraction, E6/E7 oncogene mRNA detection was performed by NucliSens® EasyQ® HPV v1 Test (bioMérieux).
Results: The results of the present study showed that E6/E7 mRNA positivity rate was 68.29 % in women tested
once and 69.56 % in women tested twice. According to tissue pathology, all samples with high-grade lesions were
positive for mRNA. Among women with low-grade lesions varied over the years from 89.28 to 84 % in women
tested once and from 77.77 to 70 % in tested twice. Among women without lesion, positivity rate maintained in
women tested once (from 50 to 41.38 %) and decreased in tested twice, from 63.63 to 44.44 %. Regarding lesion
evolution, mRNA positivity was higher in women with lesion progression (53.13 %) and in women with positive
results in two tested samples (83.33 %).
Conclusion: HPV E6/E7 mRNA detection may be an effective screening test and biomarker for cervical cancer in
women infected with these five genotypes. Nonetheless, further studies are needed to standardize as routine triage
test.
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Background
Human papillomavirus (HPV) infection is responsible of
cervical cancer, which is the second most frequent can-
cer affecting woman worldwide [1–3].
More than 100 genotypes have been described; 12 of
them are classified as high-risk genotypes (HR-HPV)
due to their high oncogenic potential [4]. Among these
HR-HPV, 16 and 18 genotypes are responsible for 76 %
of cervical cancer in Europe [5]. The most frequent in
Spain in overall women population are 16, 52, 51, 31
and 66 [6] whereas in our area, northern Spain, the most
common genotypes in women with abnormal cytology
are 16, 51, 53, 52, 39, 18, 58 and 66 [7]. On the other
hand, HPV-16, -18, -33 and -45 are more often found in
invasive cervical carcinoma rather than precancerous le-
sions [8]. Moreover, HPV-16 and HPV-33 increase the
risk of developing a grade 3 cervical intraepithelial neo-
plasia [8, 9].
HPV viral oncoprotein expression differs among infec-
tion state (active, latent, or persistent) [10, 11]. HPV E6
and E7 oncogene deregulation has been shown as a cru-
cial factor in neoplasic lesions progression [12]. More-
over, E6 and E7 oncoprotein continuous expression is
essential to maintain the neoplastic growth features [13].
To date, cervical cancer screening is based on cytology
and this has been a powerful tool to reduce the inci-
dence and mortality of this type of cancer [14, 15], but
this strategy is not completely effective to predict inva-
sive cervical cancer [16]. Recently, DNA detection is also
used [17]. Nevertheless, DNA detection gives information
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about the virus presence but not about the infection state.
Thus, it is crucial to find new biomarkers with high posi-
tive predictive value which can be used in cervical cancer
screening. E6/E7 oncogene mRNA expression could be
the most promising cervical cancer biomarker according
to current data [18]. Moreover, it has been observed that
mRNA may be more adequate than cytology for HPV in-
fected women follow-up [19, 20] owing to its prognostic
value.
The present study was designed to 1) study HPV E6/
E7 mRNA expression and analyse its relationship with
tissue pathology in order to test mRNA as an effective
biomarker for cervical cancer and 2) 2-year follow-up of
a group of women and test E6/E7 mRNA expression.
Methods
Samples
Samples from women which were referred from Con-
sultation of Sexually Transmitted Diseases and Gynaeco-
logical consultation at Basurto University Hospital
(Basque Country, Spain) were analyzed due to possible
HPV infection during the last 7 years (2007–2014). All
patients gave written and informed consent prior to
their inclusion in the study.
The samples were categorized by pathologists accord-
ing to Bethesda system: 1) negative (no lesion was
found) 2) Atypical squamous cells of undetermined sig-
nificance (ASCUS) 3) Low-grade squamous intraepithe-
lial lesion (LSIL) and 4) High-grade squamous
intraepithelial lesion (HSIL).
Molecular genotyping
Samples were analyzed with Cobas® HPV Test (Roche
Molecular Diagnostics, Mannheim, Germany) that de-
tects 14 high-risk HPV DNA genotypes, 16 and 18 sep-
arately and other 12 high-risk HPV genotypes altogether.
Samples that were positive for other HR were genotyped
with Linear Array HPV Genotyping Test kit (Roche Mo-
lecular Diagnostics), a line-blot assay that detects 37 ge-
notypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70,
71, 72, 73, 81, 82, 83, 84, IS39, and CP6108).
RNA extraction
RNA was extracted from 200 μl of samples by Nucli-
SENS Lysis Buffer and NucliSENS® miniMAG® (bioMér-
ieux, Marcy l’Etoile, France) according to manufacturer’s
instructions.
E6/E7 mRNA study
E6/E7 oncogene mRNA was detected by NucliSens®
EasyQ® HPV v1 Test (bioMérieux) following manufac-
turer’s instructions. This test detects the E6/E7 oncogene
expression of five HR-HPV genotypes (16, 18, 31, 33 and
45). The quality of extracted RNA was monitored by an
internal control: human U1 small nuclear ribonucleopro-
tein specific protein A (U1A). If neither U1A nor mRNA
were detected, the test result was analyzed as invalid. In-
valid runs were repeated once again.
Results
In the present study, E6/E7 mRNA expression was ana-
lyzed in a total of 128 samples (corresponding to 105
women). Eighty-two women’s samples were analyzed
once and in 23 women mRNA expression was studied
twice (in 2012/2013 and 2014, a total of 46 samples). All
these women were positive for HPV DNA (DNA positiv-
ity rate was 100 %).
HPV-16 was the most prevalent genotype (68.71 %,
101/147), followed by 18 (12.25 %, 18/147), 45 (8.16 %,
12/147), 31 (6.80 %, 10/147) and 33 (4.08 %, 6/147).
Nevertheless, regarding oncogene expression, HPV-33
was the most expressed (100 %, 6/6), followed by 18
(77.77 %, 14/18), 16 (70.29 %, 71/101), 31 (70 %, 7/10)
and 45 (25 %, 3/12).
mRNA expression in women tested once
Eighty-two women samples were tested for E6/E7
mRNA oncogene expression only once. The mean age
was 33.62 ± 10.57 years (range 17–63). Most of them
were infected with multiple HPV infection genotypes
(54/82) whereas 34.15 % of them had single HPV geno-
type infection.
More frequently detected genotype was 16 (67.01 %)
followed by 18, 45, 31 and 33 (11.34, 10.31, 7.21 and
4.13 %, respectively).
The E6/E7 mRNA positivity rate was 68.29 % (56/82).
The mean age of E6/E7 positive and negative women
was similar (33.53 ± 11.12 vs 33.8 ± 9.62 years). HPV 16
E6/E7 mRNA was detected in 71.42 % of positive sam-
ples (40/56), 18 in 10.71 % (6/56), 33 in 3.57 % (2/56),
16 plus 33 multiple infection in 3.57 % (2/56), and the
following genotypes were only detected in 1.78 % of
positive samples (1/56) (31; 45; 16, 18, 31 plus 45; 16, 18
plus 33; 16, 31 plus 45 and 16 plus 31 genotype).
The E6/E7 mRNA results were analyzed regarding
their cytology status. There were 77 women with cy-
tology and E6/E7 mRNA test. Pathogenicity was divided
into three groups: 1) normal or negative (no lesion was
found), 2) ASCUS and LSIL and 3) HSIL. Among E6/E7
mRNA positive samples, 47.89 % belonged to women
with ASCUS or LSIL (Fig. 1). The mRNA negative rate
for normal samples was 82.61 and 17.39 % for ASCUS
or LSIL women specimens. On the other hand, 77
women clinical follow-up was made in the following
years based on cytological results. Taking into account
samples pathogenicity, among E6/E7 mRNA positive
samples, 50.70 % belong to women with ASCUS or LSIL
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and 36.62 % with HSIL. In addition, among women
without E6/E7 mRNA expression, 65.22 % presented
normal pathology results.
Furthermore, E6/E7 mRNA was studied according to
each pathology groups (Table 1). Regarding women
follow-up (two years later) among women that had HSIL
lesions E6/E7 mRNA positivity rate was 100 % (remains
constant throughout the years) and among ASCUS and
LSIL specimens varied from 89.28 to 82.60 %. In
addition, E6/E7 mRNA negativity rate increased from
51.28 to 59.38 %.
On the other hand, lesion progression was assessed
observing cytology results of those women in the follow-
ing years (Fig. 2). Samples were categorized into three
groups: 1) persistence: samples with the same grade of
lesion (there was not a worsen process or clearance), 2)
progression: specimens with worsened lesion (the lesion
had worsened during the next years after sample collec-
tion) and 3) regression: women who had had a lesion
clearance. The mRNA positivity rate was the highest in
women who had suffered from lesion worsening process
(53.13 %) and lower in women who had had the same le-
sion (42.18 %) and who had cleared the lesion over time
(4.69 %). Moreover, there was a high correlation between
mRNA negativity rate and samples with the same grade
of lesion and clearance specimens (77.27 and 13.64 %,
respectively).
mRNA expression in women tested twice
Twenty-three women were tested twice in samples col-
lected in two different years. The mean age was 38.87 ±
11.93 (range 24–58 years). HPV single infection was
detected in 52.17 % (12/23) and multiple HPV infection
in 47.83 % (11/23). The most detected genotype was 16
(73.47 %) followed by 18 (14.29 %) and 31, 33 and 45 ge-
notypes (4.08 % of incidence each one).
The E6/E7 mRNA positivity rate was 69.56 % (32/46)
and the oncogene expression was mostly detected in
HPV-16 in 68.75 % of samples (22/32), followed by 18 in
15.63 % (5/32), 16 plus 31 multiple infection in 6.26 %
(2/32), and the followings genotypes in 3.12 % (1/32): 33;
16 plus 18 and 16, 31 plus 33.
According to E6/E7 mRNA positivity rate, 55.56 % had
some type of lesion (38.89 % ASCUS or LSIL and
16.67 % HSIL) in samples taken first (Fig. 3). However,
the percentage of women with some type of lesion and
mRNA positivity increased substantially in samples
taken during the following years (46.67 % in women with
ASCUS or LSIL and 26.66 % with HSIL). On the other
hand, E6/E7 mRNA negativity rate remained stable over
time in women with ASCUS or LSIL (from 40 to 37.5 %)
and in women without lesion (from 60 to 62.5 %).
Otherwise, concerning pathology groups, among
women with ASCUS or LSIL and HSIL mRNA rate
remained stable (from 77.77 to 70 % and 100 %)
(Table 1). Among women without lesion, the positivity
rate decreased over the years (from 63.63 to 44.44 %).
Regarding E6/E7 mRNA negativity rate, it was observed
an increase among samples without lesion (from 36.37
to 55.56 %).
Women whose diagnosis had worsened over time
were mainly positive for mRNA in two analyzed sam-
ples (83.33 %) or had a previous negative result in
mRNA but then mRNA was detected (16.67 %)
Fig. 1 Women tissue pathology conforming to E6/E7 mRNA positivity and negativity rates in women tested once. E6/E7 mRNA rates: positivity
rate for E6/E7 mRNA expression (mRNA+) and negativity rate for E6/E7 mRNA expression (mRNA-). T0 corresponds to the time when the sample
was collected and T2 corresponds to next 2 years cytology results (without E6/E7 mRNA expression test). Tissue pathology was divided into three
groups: 1) normal (no lesion), 2) Atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion
(LSIL) and 3) High-grade squamous intraepithelial lesion (HSIL)
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(Fig. 4). Otherwise, in women whose pathological re-
sults did not vary over time, E6/E7 mRNA was not
detectable in both samples in 23.53 % or mRNA was
detected in the sample taken first but not in the sec-
ond specimen in 23.53 %. Even so, mRNA in both
samples was positive in 47.06 % of women with the
same grade of lesion.
Type of infection vs. oncogenes expression
Single HPV infection was detected in 40 of 105 analyzed
women and 65 women were infected with multiple HPV
infection. Among women with single HPV infection E6/
E7 mRNA positivity rate was 67.50 % whereas that rate
was 70.77 % in women with multiple HPV infection.
The 60 % of women with single HPV infection had nor-
mal cytology results whereas the 40 % showed some le-
sion (high grade or low grade lesion). On the other
hand, the 58.33 % of women with multiple HPV infec-
tion had some lesion and only the 41.66 % has normal
cytology results. Among women with multiple HPV in-
fection and positive for E6/E7 mRNA the 19.56 % were
expressing more than one genotype oncogenes.
Discussion
Human papillomavirus is closely related with cervical
cancer. HPV infections usually show a regression in the
Table 1 E6/E7 mRNA detection according to cytology results
E6/E7mRNA expression (n/%)
Cytology result mRNA positive mRNA negative
mRNA once tested samples
(N = 77)
T0 Normal 19/48.72 20/51.28
ASCUS + LSIL 25/89.28 3/10.72
HSIL 10/100.00 0/0
T2 Normal 13/40.62 19/59.38
ASCUS + LSIL 19/82.60 4/17.40
HSIL 22/100.00 0/0.00
mRNA twice tested samples
(N = 23)
T0 Normal 7/63.63 4/36.37
ASCUS + LSIL 7/77.77 2/22.23
HSIL 3/100.00 0/0.00
T2 Normal 4/44.44 5/55.56
ASCUS + LSIL 7/70.00 3/30.00
HSIL 4/100.00 0/0.00
T0 corresponds to the time when the sample was collected and mRNA was analysed and T2 corresponds to next 2 years pathology progressions based on
cytological results. Cytology results were divided into three groups: 1) normal (no lesion), 2) Atypical squamous cells of undetermined significance (ASCUS) and
low-grade squamous intraepithelial lesion (LSIL) and 3) High-grade squamous intraepithelial lesion (HSIL)
Fig. 2 Lesion progression and its relationship with E6/E7 mRNA expression in women tested once. E6/E7 mRNA rates: positivity rate for E6/E7
mRNA expression (mRNA+) and negativity rate for E6/E7 mRNA expression (mRNA-). Lesion progression was categorized into three groups: 1)
persistence: samples with the same grade of lesion, 2) progression: specimens with worsen lesion and 3) clearance: women who had had a lesion
clearance during the next years after sample collection
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next 2 years, but few patients infected with HR-HPV ge-
notypes are at risk of developing cervical cancer [21, 22].
During carcinogenesis process, E6 and E7 oncoprotein
overexpression is the necessary factor to develop cervical
neoplasia [12]. To date, cervical cancer screening has
been one of the most effective tools to prevent this dis-
ease and nowadays, DNA testing is growing worldwide.
Nevertheless, DNA only gives information about virus
presence but makes no difference between latent and ac-
tive or persistent infections [17]. In persistent infections,
E6 and E7 genes expression is not regulated and
oncoproteins overexpression stimulates cancerous le-
sions development. Thus, it is extremely relevant to find
cervical cancer prognosis biomarker to 1) anticipate the
emergence of high-grade lesion, 2) improve screening
programs and 3) decrease the amount of women re-
ferred to colposcopy needlessly.
DNA positivity rate was less valuable in clinical use
than mRNA as it has been observed in previous studies
[19, 23, 24]. HPV mRNA test is more specific but has
less sensitivity than DNA test, hence, mRNA as triage
test could reduce HPV DNA positive women sent to
Fig. 3 Patients tissue pathology according to E6/E7 mRNA positivity and negativity rates in women that were tested twice. E6/E7 mRNA rates:
positivity rate for E6/E7 mRNA expression (mRNA+) and negativity rate for E6/E7 mRNA expression (mRNA-). T0 corresponds to results from the
first time collected sample and T2 corresponds to next years collected specimen results. Tissue pathology was classified into three groups: 1)
normal (no lesion), 2) Atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) and 3)
High-grade squamous intraepithelial lesion (HSIL)
Fig. 4 E6/E7 mRNA detection follow up in accordance with lesion progression in women that were tested twice. These women were tested
twice (in 2012/2013 and 2014). Women were classified according to E6/E7 mRNA detection in two samples: the two specimens taken in
consequent years were positive (mRNA+/mRNA+), the first sample was positive and the second one negative (mRNA+/mRNA-), both samples
were negative (mRNA-/mRNA-) and first specimen was negative and the last one positive (mRNA-/mRNA+). Lesion progression was divided into
two groups: women that had the same lesion during the time (same lesion) and women whose pathology had worsened over the time
(worsen lesion)
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colposcopy in comparison with cytology although a
lower sensitivity is assumed [19, 24]. Moreover, it has
been observed that mRNA test plus cytology has more
clinical relevance than DNA screening [23, 25].
Among mRNA positive women HPV 16 single infec-
tion transcript was the most recurrent, though, the main
majority of women tested had multiple HPV infection.
HPV 16 tended to express more than other genotypes,
which may be connected with the fact that it is consid-
ered the most carcinogenic genotype [5]. Nevertheless,
HPV-16 transcript could be the most recurrent owing to
its high incidence in the samples (68.71 %). Moreover,
after studying the expression of each genotype, HPV-33
was the most expressed genotype (100 %) followed by 18
and 16 (77.77 and 70.29 %, respectively). These results
may be due to the low number of samples with HPV-33
but even so it should be take into account. Moreover, al-
though the E6/E7 mRNA positivity rate was similar in
women infected with single and multiple HPV infection
it was observed a higher proportion of women with low
or high grade lesion among women with multiple HPV
infection. This result suggested that although oncogenes
are expressing at the same percentage in both infection
types, those women with multiple HPV infection have
more probabilities to develop cervical lesion, it may be
due to the interaction of different genotypes.
It was proved that E6/E7 mRNA positivity rate was
higher in women with high-grade lesion than in samples
with low-grade lesion or without lesion [8, 19, 26]. Be-
sides, E6/E7 mRNA negativity rate was higher in women
without lesion which means the possibility of an epi-
somal state of the virus and effective regulation of tran-
scription, which makes more likely spontaneous
clearance of the infection. Moreover, as it was assessed
in previous works, in ASCUS and LSIL samples, sensi-
tivity is higher in HPV DNA test than in HPV mRNA
test, but specificity is higher in mRNA test than DNA
test. The same happens in samples with HSIL [19]. HPV
mRNA test would gain specificity. Even so, this specifi-
city gain could be related with the fact that amplification
of viral mRNA is limited to few genotypes [27]. More-
over, these differences between specificity and sensitivity
manifest the need for further works since, only a HPV
test with high levels of sensitivity and specificity should
be implemented for use in population screening pro-
grams [28].
According to E6/E7 mRNA as cervical disease bio-
marker, mRNA positivity increased over time in speci-
mens with lesions in women tested once and in tested
twice, namely, E6/E7 mRNA positive samples showed a
malignancy progress during the next years. These results
were expected since E6 and E7 oncogene are over
expressed in precancerous lesions and it has been proved
how these oncogenes and cervical lesion severity increases
at the same time [29]. Therefore, E6/E7 mRNA may be a
very useful biomarker for cervical disease considering that
women who are E6/E7 mRNA positive should be moni-
tored more closely although their cytological results were
normal. Besides, women who only were tested once, in
samples mRNA negative, it was observed an increase of
women with ASCUS or LSIL during the next years. It may
be because these samples were negative for mRNA when
the samples was taken but over the time there was a viral
transcription deregulation developing cervical lesions.
Nevertheless, in women who were tested twice, there
was no difference in mRNA negativity between samples
tested first and specimens tested one or two years later,
so it seemed that there were a significant number of
specimens that had minor cervical lesions but were
negative for E6/E7 mRNA. This event could be related
with the fact that low-grade cervical lesions normally
disappears in a few months without treatment [30]. Even
so mRNA test has been found more specific and clinic-
ally more useful than DNA test in women with low
grade lesions [24].
Finally, E6/E7 mRNA could be a good prognosis marker
since it was observed that women who were positive for
E6/E7 mRNA had more probabilities to develop lesion
progression. Besides, women in which samples mRNA
was negative had more possibilities to remain the same
pathological grade or have infection clearance. These find-
ings are in concordance with previous studies where E6/
E7 mRNA was considered a short-term prognostic factor
for high-grade lesions [31]. Nevertheless, according to
Discacciati et al., E6/E7 mRNA is not a long-term prog-
nostic factor since women who were positive for DNA
and negative for E6/E7 mRNA may become DNA and E6/
E7 mRNA positive women which would change their
pathological results [31].
Conclusions
E6 and E7 oncogene mRNA detection seems to be a use-
ful instrument as a triage test in women infected with
HPV-16, -18, -31, -33 or -45 genotypes. Moreover, it
could be a promising biomarker since it has been proved
its relationship with lesion grade, making possible the
reduction of HPV positive women referred to colpos-
copy. Even so, further studies are needed to use Nucli-
Sens® EasyQ® HPV v1 Test as standard screening
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